AstraZeneca (MEX:AZNN) Long-Term Debt: MXN440,972 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:AZNN AstraZeneca PLC MEX:AZNN
87 GF Score
Price MXN1,628.00
GF Value MXN1,734.39
! 1 Warning Sign
View Full Analysis

What is AstraZeneca Long-Term Debt?

AstraZeneca MEX:AZNN +1.25% 87 Long-Term Debt is MXN440,972 Mil as of Mar. 2026. GuruFocus rates MEX:AZNN with a GF Score™ of 87/100 and a GF Value™ of MXN1,734.39. The stock has 1 warning sign investors should review.

AstraZeneca's Long-Term Debt for the quarter that ended in Mar. 2026 was MXN440,972 Mil.

AstraZeneca's quarterly Long-Term Debt declined from Sep. 2025 (MXN453,102 Mil) to Dec. 2025 (MXN445,011 Mil) and declined from Dec. 2025 (MXN445,011 Mil) to Mar. 2026 (MXN440,972 Mil).

AstraZeneca's annual Long-Term Debt increased from Dec. 2023 (MXN379,629 Mil) to Dec. 2024 (MXN552,801 Mil) but then declined from Dec. 2024 (MXN552,801 Mil) to Dec. 2025 (MXN445,011 Mil).

AstraZeneca  (MEX:AZNN) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

AstraZeneca Long-Term Debt Related Terms

AstraZeneca Long-Term Debt Historical Data

* Premium members only.

The historical data trend for AstraZeneca's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AstraZeneca Long-Term Debt Chart

AstraZeneca Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 577,140.88 447,725.64 379,629.06 552,801.18 445,010.88

AstraZeneca Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 546,070.28 465,344.85 453,101.74 445,010.88 440,971.65
MEX:AZNN
87GF Score
AstraZeneca PLC MEX:AZNN
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of MXN440,972 Mil mean?
AstraZeneca (MEX:AZNN) has a Long-Term Debt of MXN440,972 Mil as of Mar. 2026.
Is AstraZeneca's Long-Term Debt too high?
AstraZeneca's current Long-Term Debt is MXN440,972 Mil. Overall, AstraZeneca has a GF Score™ of 87/100, reflecting its overall financial health beyond just this single metric.
How does AstraZeneca's Long-Term Debt compare to LLY and JNJ?
AstraZeneca's Long-Term Debt of MXN440,972 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. AstraZeneca's current Long-Term Debt is MXN440,972 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AstraZeneca stock overvalued right now?
AstraZeneca (MEX:AZNN) has a current Long-Term Debt of MXN440,972 Mil. The stock's GF Value™ is MXN1,734.39, compared to a current price of MXN1,628.00 — trading 6.1% below its estimated fair value. The current Long-Term Debt is MXN440,972 Mil. AstraZeneca's overall GF Score™ is 87/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For AstraZeneca (MEX:AZNN), the current Long-Term Debt is MXN440,972 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AstraZeneca (MEX:AZNN) Overvalued in 2026?

Based on GuruFocus' analysis, AstraZeneca stock appears to be undervalued. The current stock price of MXN1,628.00 is trading 6.1% below its estimated GF Value™ of MXN1,734.39.

Key valuation signals for MEX:AZNN:

  • Long-Term Debt: MXN440,972 Mil
  • GF Value™: MXN1,734.39 vs. price of MXN1,628.00 (6.1% below fair value)
  • GF Score™: 87/100 with 1 warning sign

No single metric tells the full story. See the MEX:AZNN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AstraZeneca Business Description

Address 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
87GF Score

Get the complete analysis for MEX:AZNN

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,628.00
Price
MXN1,734.39
GF Value